Two medicines, side by side
Alfuzosin vs aspirin
Alfuzosin is labeled for enlarged prostate (bph); aspirin for pain, cough and cold and fever. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of alfuzosin since 2003 and of aspirin since 1965. Pharmacies paid $0.105 per alfuzosin HCl ER 10 mg tablet and $0.0142 per aspirin ec 81 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like.
Check it at the source: the alfuzosin FDA label on DailyMed (effective December 5, 2024); the aspirin FDA label on DailyMed (effective September 9, 2025).
Highlights of the alfuzosin record
Alfuzosin (Uroxatral) · label of December 5, 2024
Used for
From the label: indicationsUROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. ( 1 ) Important Limitations of Use: UROXATRAL is not indicated for treatment of hypertension. ( 1.1 ) UROXATRAL is not indicated for use in the pediatric population. […]
On the market
- Earliest approval on file
- June 12, 2003
- Generic labelers
- 10 labelers
- Pharmacy cost
- $0.105 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the aspirin record
Aspirin (Measurin) · label of September 9, 2025
Used for
From the label: indicationsTemporarily relieves headache toothache pain and fever of colds muscle pain menstrual pain minor pain of arthritis
On the market
- Earliest approval on file
- June 25, 1965
- Generic labelers
- none listed
- Pharmacy cost
- $0.0142 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 1
Source: FDA drug labels via openFDA (Alfuzosin label of December 5, 2024, Aspirin label of September 9, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do alfuzosin and aspirin differ on the record?
Generics: alfuzosin since 2011; aspirin none approved (Drugs@FDA).
| Alfuzosin | Aspirin | |
|---|---|---|
| Labeled for | Enlarged prostate (BPH) | Pain, Cough and cold, Fever |
| Pharmacologic class | alpha-Adrenergic Blocker | n/a |
| How it works (label) | Alfuzosin is a selective antagonist of post-synaptic alpha 1 -adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. | n/a |
| Half-life (label) | Following oral administration of UROXATRAL 10 mg tablets, the apparent elimination half-life is 10 hours. | n/a |
| Earliest approval on file (Drugs@FDA) | June 12, 2003 | June 25, 1965 |
| First generic approved | July 18, 2011 | none |
| Generic labelers (NDC) | 10 labelers | none listed |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.105 per tablet (Alfuzosin HCl ER 10 mg tablet) | $0.0142 per tablet (Aspirin ec 81 mg tablet) |
| 12-month price change | -0.1% | -2% |
| Boxed warning | No | No |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 1 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 5,746 | 534,208 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to alfuzosin
- every medicine labeled for the same conditions